Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis. A collaboration with MSD will focus on the Phase II evaluation of the combination of BO-112, Highlight’s lead program, and KEYTRUDA®...
Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that it has raised $31 million (€27 million) in a Series A financing round. Vico will use this funding to further advance...
“We progressed from initial compound discovery to the clinic in just two years, and early findings from our first clinical study of CYT-0851 suggest that we will be able to maintain this exceptional momentum,” said Markus Renschler, M.D., Cyteir president and CEO. “We’re excited to...
The grant will be used to hire an Innovation Associate who will work on the implementation of innovative (bio)analytical techniques with high spatial resolution to better understand the microdistribution and local behaviour of CriPec® nanomedicines within the tumour microenvironment (TME)....
QurAlis' announces the results of extensive pre-clinical studies on its lead program for ALS patients: QRA-244 shows comparable effects to retigabine and dramatic reductions in side effects....
Accent Therapeutics and AstraZeneca (LSE/STO/NYSE: AZN) will collaborate to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer. The collaboration combines Accent’s expertise as a leader in the biology, target identification and drug discovery of RMP-targeting therapies with AstraZeneca’s...
The financing was led by LS Polaris Innovation Fund, lead seed investor Mission BioCapital, INKEF Capital and the Dementia Discovery Fund, and co-led by Droia Ventures. Additional new investors include Mitsui Global Investment and Dolby Family Ventures, joined by investments from existing investors Amgen Ventures,...
Proceeds from the financing will be used to advance the development of Accent’s novel therapies targeting RNA-modifying proteins (RMPs), including its lead programs METTL3 and ADAR1, and to continue to expand its pipeline in the rich target space of RNA modification....
Highlight Therapeutics (“Highlight”), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces the appointment of Carlos Paya, MD, PhD, as Executive Chairman with immediate effect. The Company has also significantly expanded its Advisory Board with a number of internationally-renowned scientific and industry leaders. In...
Montis was founded by Droia Ventures, VIB and KU Leuven based on the foundational science discovered by the labs of Peter Carmeliet (VIB-KU Leuven) and Massimiliano Mazzone (VIB-KU Leuven). For the seed financing, the founders were joined by new investors Polaris Partners, ALSA Ventures and...